Grifols (GRFS) Total Debt Growth (3y) (2012 - 2025)
Grifols (GRFS) Total Debt Growth (3y) (2012 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 2.45% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 5.09% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 13.46% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -19.32% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 51.71% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -0.51% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -0.71% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -1.11% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 0.14% |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | 0.60% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.60% |
| Dec 31, 2024 | 41.80% |
| Dec 31, 2023 | 14.16% |
| Dec 31, 2022 | 181.43% |
| Dec 31, 2021 | 106.03% |
| Dec 31, 2020 | 236.21% |
| Dec 31, 2019 | -55.00% |
| Sep 30, 2019 | 15.71% |
| Dec 31, 2018 | -57.58% |
| Sep 30, 2018 | 12.74% |
| Jun 30, 2018 | 3,124.89% |
| Mar 31, 2018 | 17.58% |
| Dec 31, 2017 | -66.17% |
| Jun 30, 2017 | 7.99% |
| Dec 31, 2016 | 10.16% |
| Jun 30, 2016 | 13.21% |
| Mar 31, 2016 | -77.38% |
| Dec 31, 2015 | 12.48% |
| Sep 30, 2015 | 13.01% |
| Jun 30, 2015 | -96.10% |